GlassScriptPhysician profile
Inessa Khaykis
NPI 1821204686
$16,111.82
in general payments reported to CMS, 2019-2025
45 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,303 · 2020: $2,211 · 2021: $2,440 · 2022: $3,426 · 2023: $3,136 · 2024: $2,196 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,731.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,711.99 | 2019-2024 | Plenvu, Xifaxan, Trulance |
| Abbvie INC. | $3,558.58 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,368.48 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $942.87 | 2019-2024 | Stelara |
| Celgene Corporation | $743.31 | 2019-2024 | Zeposia |
| Pfizer INC. | $599.48 | 2019-2025 | |
| Qol Medical, LLC | $567.22 | 2019-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $515.03 | 2019-2025 | Clenpiq, Rebyota |
| Daiichi Sankyo INC. | $375.82 | 2019-2023 | Injectafer |
| Redhill Biopharma INC. | $370.48 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $338.85 | 2019-2024 | Linzess |
| Novo Nordisk INC | $263.39 | 2024-2025 | Wegovy |
| Ardelyx, INC. | $232.22 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $231.01 | 2023-2025 | Zepbound, Omvoh, Mounjaro |
| Merck Sharp & Dohme LLC | $194.50 | 2019-2024 | Dificid |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inessa Khaykis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.